<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MYC is a transcription factor that regulates many critical genes for cell proliferation, differentiation, and biomass accumulation </plain></SENT>
<SENT sid="1" pm="."><plain>MYC is one of the most prevalent oncogenes found to be altered in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, being deregulated in about 50 % of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Although MYC deregulation has been more frequently associated to <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> than to <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, a body of evidence has been gathered showing that MYC plays a relevant role in <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> derived from the myeloid compartment </plain></SENT>
<SENT sid="3" pm="."><plain>The myeloid leukemogenic activity of MYC has been demonstrated in different murine models </plain></SENT>
<SENT sid="4" pm="."><plain>Not surprisingly, MYC has been found to be amplified or/and deregulated in the three major types of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>: <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, including <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we review the recent literature describing the involvement of MYC in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid tumors</z:e> </plain></SENT>
</text></document>